PC
CRSP icon

Plaisance Capital’s CRISPR Therapeutics CRSP Stock Holding History

Plaisance Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25,200
Closed -$1.58M – 28
2022
Q1 		$1.58M Buy
+25,200
New +$1.58M 1.14% 13
2021
Q4 		– Sell
-4,000
Closed -$448K – 38
2021
Q3 		$448K Hold
4,000
– – 0.32% 28
2021
Q2 		$484K Buy
+4,000
New +$486K 0.24% 49

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Plaisance Capital's CRSP Position: Q3 2021 in Review

Plaisance Capital sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 15,230 shares — an estimated $1.91M sold.

Plaisance Capital first reported a position in CRSP in Q2 2021 and held it in 1 quarter. The position peaked at $2.47M in Q2 2021. 474 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Plaisance Capital reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Plaisance Capital sold 15,230 CRISPR Therapeutics shares in Q3 2021, an estimated $1.91M.
  • Plaisance Capital first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 1 quarter.
  • Plaisance Capital's CRISPR Therapeutics position peaked at $2.47M in Q2 2021.
  • 474 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Plaisance Capital's 13F filing for Q3 2021, filed 15 Nov 2021.